MCID: END084
MIFTS: 45

Endocrine System Disease

Categories: Endocrine diseases, Immune diseases

Aliases & Classifications for Endocrine System Disease

MalaCards integrated aliases for Endocrine System Disease:

Name: Endocrine System Disease 12 15 17
Abnormality of the Endocrine System 29
Disorder of Endocrine System 29
Endocrine System Diseases 43

Classifications:



External Ids:

Disease Ontology 12 DOID:28
ICD9CM 34 259.9
MeSH 43 D004700
NCIt 49 C3009
SNOMED-CT 67 362969004
ICD10 32 E34.9
UMLS 71 C0014130

Summaries for Endocrine System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in endocrine glands which secretes a type of hormone directly into the bloodstream to regulate the body.

MalaCards based summary : Endocrine System Disease, also known as abnormality of the endocrine system, is related to thyroid gland disease and pancreas disease, and has symptoms including cushingoid facies, pathological conditions, signs and symptoms and breast pain male. An important gene associated with Endocrine System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Insulin glargine and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include endocrine glands which secretes a type of hormone directly into the bloodstream to regulate the body, testes and bone.

Related Diseases for Endocrine System Disease

Diseases in the Endocrine System Disease family:

Autoimmune Disease of Endocrine System

Diseases related to Endocrine System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 thyroid gland disease 33.0 SERPINA3 MIR9-1 MIR222 MIR221 MIR199A1 MIR17
2 pancreas disease 32.9 SERPINA3 MIR9-1 MIR483 MIR31 MIR30A MIR221
3 adrenal gland disease 32.9 SERPINA3 MIR483 MIR210 INS CCR6
4 pituitary gland disease 32.9 RNU4ATAC MIR210 MIR21 INS H2AC18
5 alopecia, neurologic defects, and endocrinopathy syndrome 11.3
6 precocious puberty, male-limited 11.1
7 cortisone reductase deficiency 11.1
8 parathyroid gland disease 11.1
9 intestinal benign neoplasm 10.9 SERPINA3 MIR483 MIR21 MIR199A1 MIR196A1 MIR17
10 ovary epithelial cancer 10.9 SERPINA3 MIR9-1 MIR483 MIR30A MIR21 MIR199A1
11 malignant ovarian surface epithelial-stromal neoplasm 10.9 SERPINA3 MIR9-1 MIR483 MIR30A MIR21 MIR199A1
12 bone sarcoma 10.9 SERPINA3 MIR9-1 MIR31 MIR21 MIR199A1 MIR17
13 laryngeal disease 10.9 MIR9-1 MIR31 MIR21 MIR196A1 MIR17 MIR142
14 leukocyte disease 10.9 SERPINA3 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
15 mouth disease 10.9 SERPINA3 MIR9-1 MIR31 MIR221 MIR21 MIR199A1
16 gastrointestinal system benign neoplasm 10.9 SERPINA3 MIR483 MIR30A MIR21 MIR199A1 MIR196A1
17 spinal disease 10.9 SERPINA3 RNU4ATAC MIR9-1 MIR21 MIR199A1 MIR196A1
18 endocrine organ benign neoplasm 10.9 SERPINA3 MIR483 MIR221 MIR210 MIR21 MIR199A1
19 bone inflammation disease 10.9 SERPINA3 MIR483 MIR30A MIR21 MIR199A1 MIR196A1
20 bone cancer 10.9 SERPINA3 MIR9-1 MIR31 MIR210 MIR21 MIR199A1
21 bone marrow cancer 10.9 MIR9-1 MIR483 MIR30A MIR21 MIR199A1 MIR196A1
22 autonomic nervous system neoplasm 10.9 SERPINA3 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1
23 bile duct adenocarcinoma 10.9 SERPINA3 MIR9-1 MIR483 MIR31 MIR30A MIR21
24 peripheral nervous system neoplasm 10.9 SERPINA3 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1
25 bladder disease 10.9 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
26 mature b-cell neoplasm 10.9 MIR9-1 MIR483 MIR222 MIR199A1 MIR196A1 MIR17
27 inherited metabolic disorder 10.9 SERPINA3 MIR9-1 MIR483 MIR30A MIR21 MIR199A1
28 myeloma, multiple 10.9 SERPINA3 MIR9-1 MIR483 MIR30A MIR21 MIR199A1
29 tongue disease 10.9 MIR483 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
30 cervix disease 10.9 MIR9-1 MIR483 MIR31 MIR30A MIR21 MIR199A1
31 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.9 SERPINA3 RNU4ATAC MIR9-1 MIR483 MIR21 MIR199A1
32 muscular disease 10.9 SERPINA3 RNU4ATAC MIR9-1 MIR221 MIR199A1 MIR196A1
33 lung cancer susceptibility 3 10.9 SERPINA3 MIR9-1 MIR483 MIR31 MIR30A MIR21
34 muscle tissue disease 10.9 SERPINA3 RNU4ATAC MIR9-1 MIR221 MIR199A1 MIR142
35 biliary tract disease 10.9 SERPINA3 MIR9-1 MIR483 MIR30A MIR222 MIR199A1
36 bile duct disease 10.9 SERPINA3 MIR9-1 MIR483 MIR30A MIR222 MIR199A1
37 squamous cell carcinoma, head and neck 10.9 MIR9-1 MIR483 MIR31 MIR30A MIR221 MIR210
38 autosomal genetic disease 10.9 SERPINA3 RNU4ATAC MIR9-1 MIR483 MIR21 MIR199A1
39 gallbladder disease 10.9 SERPINA3 MIR483 MIR199A1 MIR196A1 MIR17 MIR126
40 colonic disease 10.9 SERPINA3 MIR9-1 MIR483 MIR31 MIR30A MIR221
41 nasopharyngeal disease 10.9 MIR9-1 MIR483 MIR31 MIR30A MIR21 MIR199A1
42 esophageal disease 10.9 MIR483 MIR31 MIR30A MIR21 MIR199A1 MIR196A1
43 oral cavity cancer 10.9 MIR9-1 MIR483 MIR31 MIR30A MIR21 MIR199A1
44 pleural disease 10.9 SERPINA3 MIR199A1 MIR17 MIR125A H2AC18 CCR6
45 central nervous system cancer 10.9 SERPINA3 MIR9-1 MIR30A MIR222 MIR21 MIR199A1
46 heart valve disease 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR126 H2AC18
47 skin disease 10.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
48 chromosomal disease 10.9 SERPINA3 MIR9-1 MIR483 MIR21 MIR196A1 MIR17
49 central nervous system disease 10.9 SERPINA3 MIR9-1 MIR30A MIR221 MIR210 MIR21
50 lipid storage disease 10.9 SERPINA3 MIR483 MIR21 MIR199A1 MIR142 INS

Graphical network of the top 20 diseases related to Endocrine System Disease:



Diseases related to Endocrine System Disease

Symptoms & Phenotypes for Endocrine System Disease

UMLS symptoms related to Endocrine System Disease:


cushingoid facies, pathological conditions, signs and symptoms, breast pain male

Drugs & Therapeutics for Endocrine System Disease

Drugs for Endocrine System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin glargine Approved Phase 4 160337-95-1
2
Insulin aspart Approved Phase 4 116094-23-6 16132418
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Norepinephrine Approved Phase 4 51-41-2 439260
8
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
11 Insulin degludec, insulin aspart drug combination Phase 4
12 Insulin, Long-Acting Phase 4
13 Antidepressive Agents Phase 4
14 Hydrocortisone 17-butyrate 21-propionate Phase 4
15 Hydrocortisone hemisuccinate Phase 4
16 Antimetabolites Phase 4
17 Epinephryl borate Phase 4
18 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
19 Serotonin Uptake Inhibitors Phase 4
20 Hypoglycemic Agents Phase 4
21 Sodium-Glucose Transporter 2 Inhibitors Phase 4
22 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)... Phase 4
23
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
24
Metformin Approved Phase 3 657-24-9 14219 4091
25
Zinc Approved, Investigational Phase 3 7440-66-6 32051
26
Glimepiride Approved Phase 3 93479-97-1 3476
27
Saxagliptin Approved Phase 3 361442-04-8 11243969
28
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
29
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
30
Glucagon Approved Phase 3 16941-32-5
31
Dulaglutide Approved, Investigational Phase 3 923950-08-7
32
Calcium carbonate Approved, Investigational Phase 3 471-34-1
33
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
34
Linagliptin Approved Phase 3 668270-12-0 10096344
35
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
36 Nutmeg Approved Phase 3
37
Bupropion Approved Phase 3 34911-55-2, 34841-39-9 444
38
tannic acid Approved Phase 3 1401-55-4
39
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
40
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
41
gastric inhibitory polypeptide Investigational Phase 3 100040-31-1
42 Antihypertensive Agents Phase 3
43 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 3
44 Insulin, Short-Acting Phase 3
45 Anti-Arrhythmia Agents Phase 3
46 Sitagliptin Phosphate Phase 3
47 Angiotensin Receptor Antagonists Phase 3
48 Angiotensin-Converting Enzyme Inhibitors Phase 3
49 Growth Hormone-Releasing Hormone Phase 3
50 Glucagon-Like Peptide 1 Phase 3

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Children Growth Hormone Deficiency: A Multicenter, Randomized, Parallel, Dose-control Clinical Trial II Unknown status NCT02908958 Phase 4
2 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Open-label, Phase IV Clinical Trial With Different Administration Dosage of PEG Somatropin Unknown status NCT03249480 Phase 4
3 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Randomized, Open-label, Parallel Phase IV Clinical Trial With Different Administration Frequency of PEG Somatropin Unknown status NCT02976675 Phase 4
4 Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
5 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ
6 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
7 Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. Recruiting NCT03491696 Phase 4 Metyrapone
8 Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism Active, not recruiting NCT01848171 Phase 4 L-thyroxine
9 The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study Active, not recruiting NCT01831869 Phase 4 L-thyroxine
10 The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Not yet recruiting NCT04071626 Phase 4 Ertugliflozin 5 mg;Placebo oral tablet
11 Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency Terminated NCT01698944 Phase 4 somatropin
12 Placebo Controlled Trial on the Efficacy of Growth Hormone Replacement Therapy in Patients With Growth Hormone Deficiency After Traumatic Brain Injury. Terminated NCT00555009 Phase 4 Genotropin;Placebo
13 Head Trauma With Traumatic Brain Injury (TBI): A Multicenter, Phase IV Study to Evaluate the Effects of Genotropin in Adult Patients With Growth Hormone Deficiency (GHD) Caused by Trauma and/or Head Injury Terminated NCT00638053 Phase 4
14 Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study. Completed NCT00163215 Phase 3 Somatropin
15 Extended Clinical Study of LY137998 [Somatropin (Recombinant DNA Origin)] in Adults With Growth Hormone Deficiency Completed NCT00191360 Phase 3 Somatropin
16 Phase III of the Comparative Study on the Efficacy and Safety of Recombinant Somatropin Administered to Patients With Adult Growth Hormone Deficiency Completed NCT02693522 Phase 3 somatropin;Eutropin
17 Investigation of the Efficacy and Safety of NN-220 for 48 Weeks in Adults With Growth Hormone Deficiency Completed NCT00184743 Phase 3 somatropin
18 Effect of Two Years of Treatment With Norditropin® SimpleXx® on Bone Mineral Density in Young Adults With Childhood-Onset Growth Hormone Deficiency Completed NCT00184678 Phase 3 somatropin
19 Effect of Growth Hormone in Children With Growth Hormone Deficiency and Idiopathic Short Stature Completed NCT00262249 Phase 3 somatropin
20 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency. Completed NCT00294619 Phase 3 growth hormone
21 Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency Completed NCT00519558 Phase 3 somatropin
22 Randomized Controlled Trial Comparing the Metabolic Efficiency of Allogeneic Pancreatic Islet Transplantation to Intensive Insulin Therapy for the Treatment of Type 1 Diabetes Completed NCT01148680 Phase 3
23 A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency Completed NCT00596037 Phase 3 Growth hormone - LB03002
24 Efficacy and Safety of a High Dosage Compared to the Label Dosage of Humatrope in Early Pubertal Stage Children With Growth Hormone Deficiency Completed NCT00191165 Phase 3 Somatropin;Somatropin
25 A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise Completed NCT00736879 Phase 3 Dapagliflozin;Placebo
26 Norditropin® and Norditropin® Cartridges: An Open-Label, Randomized, Comparative Safety and Efficacy Trial in Children With Growth Hormone Deficiency Completed NCT01502124 Phase 3 somatropin;somatropin
27 Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men Completed NCT02081300 Phase 3 Oral testosterone undecanoate, LPCN 1021;Topical testosterone gel 1.62 %
28 A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency Completed NCT03075644 Phase 3 somapacitan;Norditropin
29 fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD Completed NCT03305016 Phase 3 TransCon hGH
30 A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency Completed NCT02382939 Phase 3 somapacitan;somatropin
31 A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Completed NCT01841697 Phase 3 Omarigliptin;Sitagliptin;Placebo to omarigliptin;Placebo to Sitagliptin;Open-label Metformin;Open-label Glimepiride
32 A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control Completed NCT00859898 Phase 3 Dapagliflozin;Metformin XR;Metformin XR;dapagliflozin matching Placebo;metformin HCl Modified Release matching Placebo
33 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone Completed NCT00528879 Phase 3 Dapagliflozin;Placebo;Metformin
34 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Completed NCT01137474 Phase 3 Dapagliflozin;Placebo-matching dapagliflozin
35 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication Completed NCT01195662 Phase 3 Dapagliflozin;Placebo matching Dapagliflozin
36 A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD) Completed NCT02781727 Phase 3 Once weekly subcutaneous injection of TransCon hGH;Once daily subcutaneous injection of Genotropin
37 A Randomised, Open-label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety for 12 Months of Zomacton to Genotropin in Children With Idiopathic Growth Hormone Deficiency Completed NCT00884000 Phase 3 Genotropin;Zomacton
38 A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period Completed NCT02229851 Phase 3 somapacitan;somatropin;placebo
39 Pegylated Somatropin in the Treatment of Children With Growth Hormone Deficient:A Multicenter, Randomized, Open-label, Controlled Phase Ⅲ Clinical Trial Completed NCT01495468 Phase 3
40 A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control Completed NCT02273050 Phase 3 Saxagliptin 5 mg;Placebo 5 mg for Saxagliptin;Placebo 500 mg for metformin (with titration);Metformin 500 mg with titration
41 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Completed NCT01814748 Phase 3 Omarigliptin;Placebo to omarigliptin;Metformin
42 Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT) Completed NCT02558829 Phase 3 Macimorelin;Insulin
43 A Phase III, Multicentric, Open-label, Randomised, Comparative, Parallel Group Study of (GHRH + Arginine) Combination Test vs. Insulin Tolerance Test (ITT) in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) Completed NCT01060488 Phase 3
44 Efficacy and Safety of CinnaGen Recombinant Human Growth Hormone (CinnaTropin®) in Comparison With Novo Nordisk Growth Hormone (Nordilet®) Product in Pre-Pubertal Children With Idiopathic Growth Hormone Deficiency (IGHD) Completed NCT03223025 Phase 3 CinnaTropin®;Nordilet®
45 A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS) Completed NCT00109733 Phase 3
46 A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency Completed NCT03874013 Phase 3 MOD-4023;Genotropin
47 A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Chinese Subjects in China With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination With Metformin Completed NCT02104804 Phase 3 Saxagliptin 5mg;Placebo for Saxagliptin
48 The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT) Recruiting NCT04255433 Phase 3 Tirzepatide;Dulaglutide
49 The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China Recruiting NCT04326374 Phase 3 TransCon hGH;daily hGH
50 Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4) Active, not recruiting NCT03730662 Phase 3 Tirzepatide;Insulin Glargine

Search NIH Clinical Center for Endocrine System Disease

Cochrane evidence based reviews: endocrine system diseases

Genetic Tests for Endocrine System Disease

Genetic tests related to Endocrine System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Endocrine System 29
2 Disorder of Endocrine System 29

Anatomical Context for Endocrine System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Endocrine System Disease:

19
Endocrine Glands Which Secretes A Type Of Hormone Directly Into The Bloodstream To Regulate The Body

MalaCards organs/tissues related to Endocrine System Disease:

40
Testes, Bone, Brain, Heart, Lung, Thyroid, Liver

Publications for Endocrine System Disease

Articles related to Endocrine System Disease:

(show all 34)
# Title Authors PMID Year
1
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. 61
32156648 2020
2
Molecular mechanisms underlying zinc oxide nanoparticle induced insulin resistance in mice. 61
31519126 2020
3
Gut Microbiota and Endocrine Disorder. 61
32323184 2020
4
[Analysis and strategies of rapid response team in the Fourth People's Hospital of Shenyang]. 61
32148241 2020
5
Involvement of GJA1 and Gap Junctional Intercellular Communication between Cumulus Cells and Oocytes from Women with PCOS. 61
32190671 2020
6
Parameters Related to Lumbar Puncture Do not Affect Occurrence of Postdural Puncture Headache but Might Influence Its Clinical Phenotype. 61
31562971 2020
7
Ramadan and Health. Bibliometric study of the biomedical literature indexed in «Medline» database. 61
31691944 2019
8
Characteristics of olfactory ensheathing cells and microarray analysis in Tupaia belangeri (Wagner, 1841). 61
31257532 2019
9
The anti-hyperglycemia effects of Rhizoma Coptidis alkaloids: A systematic review of modern pharmacological studies of the traditional herbal medicine. 61
30836124 2019
10
An ultrasensitive sensor based on quantitatively modified upconversion particles for trace bisphenol A detection. 61
30390111 2019
11
[Effect of anthropo-technogenic load on medico-social aspects of primary morbidity and disability of population.] 61
30607922 2018
12
Evaluation of the carcinogenic risks at the influence of POPs. 61
28854146 2017
13
Medical comorbidities in children and adolescents with autism spectrum disorders and attention deficit hyperactivity disorders: a systematic review. 61
28674760 2017
14
Analysis on nutritional risk screening and influencing factors of hospitalized patients in central urban area. 61
28786068 2017
15
[Peculiarities of disorders in physical development of children consuming drinking water with increased nitrate content]. 61
30645861 2017
16
Influence of PCOS in Obese vs. Non-Obese women from Mesenchymal Progenitors Stem Cells and Other Endometrial Cells: An in silico biomarker discovery. 61
28539732 2017
17
Binge-eating disorder in the Swedish national registers: Somatic comorbidity. 61
27642179 2017
18
[Study on skeletal muscle mass of 1 836 check-up adults and its association with age in Qiqihar]. 61
26957241 2016
19
[Features of physical development of girls residing in the altai territory with the different level of the environmental load]. 61
29424996 2016
20
[Clinical analysis for systemic complications of patients in the dental emergency room]. 61
25882958 2015
21
[Etiologies and clinical features of 19 cases with bilateral acute sensorineural hearing loss]. 61
25764919 2015
22
[High-tech medical care in surgical endocrinology]. 61
25146543 2014
23
[The role of selenium in endocrine system diseases]. 61
24095912 2013
24
[The structure of emergency calls of the intensive care team depending on age and gender of patients appealed for urgent medical aid]. 61
22168066 2011
25
[Working despite having diseases: Endocrine system diseases and metabolic diseases]. 61
21584990 2010
26
[Etiological analysis and individualized treatment of pharyngeal paraesthesia]. 61
19894556 2009
27
[Endocrinal dysfunctions in liver failure of different etiologies and during interferon therapy in patients with chronic hepatitis B and C]. 61
18634398 2008
28
[The potential dangers of endocrinal disorders]. 61
11852452 2002
29
[Coenzyme Q--clinical significance]. 61
8999700 1994
30
Increased deaths due to endocrine system diseases and allergies among mothers of dizygotic twins. 61
6538639 1984
31
[Dental treatment in patients with endocrine system diseases]. 61
6458900 1981
32
[Compensation of the hormonal and metabolic disorders as a general principle in treating endocrine system diseases]. 61
6892937 1980
33
[Acute crisis in endocrine system diseases]. 61
4572045 1973
34
[Endocrine system diseases and estrogen]. 61
18860221 1947

Variations for Endocrine System Disease

Expression for Endocrine System Disease

Search GEO for disease gene expression data for Endocrine System Disease.

Pathways for Endocrine System Disease

Pathways related to Endocrine System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 MIR222 MIR221 MIR210 MIR17
2 11.93 MIR9-1 MIR483 MIR31 MIR30A MIR222 MIR221
3 11.03 MIR222 MIR221 MIR210
4 10.84 MIR9-1 MIR222 MIR221 MIR199A1

GO Terms for Endocrine System Disease

Cellular components related to Endocrine System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.5 MIR30A MIR222 MIR221 MIR21 MIR17 MIR126
2 extracellular space GO:0005615 9.47 SERPINA3 MIR31 MIR30A MIR222 MIR221 MIR210

Biological processes related to Endocrine System Disease according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.95 MIR30A MIR210 MIR21 INS
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 MIR222 MIR221 MIR21 MIR126
3 negative regulation of inflammatory response GO:0050728 9.88 MIR31 MIR222 MIR221 MIR142 MIR126
4 positive regulation of protein kinase B signaling GO:0051897 9.85 MIR222 MIR221 MIR21 MIR199A1 MIR126 INS
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 MIR21 MIR126 INS
6 gene silencing by miRNA GO:0035195 9.83 MIR10B MIR125A MIR126 MIR142 MIR17 MIR196A1
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.81 MIR483 MIR221 MIR199A1 MIR196A1
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.8 MIR222 MIR221 MIR21 MIR17
9 positive regulation of angiogenesis GO:0045766 9.8 MIR31 MIR30A MIR210 MIR21 MIR199A1 MIR126
10 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.79 MIR30A MIR222 MIR221
11 positive regulation of epithelial to mesenchymal transition GO:0010718 9.79 MIR222 MIR221 MIR21
12 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.78 MIR31 MIR126 MIR10B
13 positive regulation of epithelial cell migration GO:0010634 9.77 MIR222 MIR221 CCR6
14 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.77 MIR222 MIR221 MIR125A
15 negative regulation of vascular endothelial growth factor production GO:1904046 9.74 MIR199A1 MIR17 MIR125A
16 positive regulation of sprouting angiogenesis GO:1903672 9.73 MIR31 MIR126 MIR125A
17 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.7 MIR21 MIR126 MIR10B
18 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.67 MIR21 INS
19 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.66 MIR199A1 MIR17
20 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.66 MIR21 MIR125A
21 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.65 MIR199A1 MIR17
22 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 MIR31 MIR30A MIR221 MIR210 MIR126
23 negative regulation of cell adhesion molecule production GO:0060354 9.64 MIR222 MIR221
24 positive regulation of axon regeneration GO:0048680 9.64 MIR222 MIR221
25 positive regulation of metalloendopeptidase activity GO:1904685 9.63 MIR21 MIR17
26 negative regulation by host of viral genome replication GO:0044828 9.63 MIR222 MIR221
27 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR210 MIR21 MIR17
28 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.61 MIR222 MIR221 MIR21
29 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.58 MIR222 MIR221
30 positive regulation of Schwann cell migration GO:1900149 9.58 MIR222 MIR221
31 negative regulation of interleukin-21 production GO:0032705 9.58 MIR222 MIR221 MIR21
32 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.55 MIR222 MIR221
33 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.54 MIR222 MIR221
34 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.46 MIR31 MIR222 MIR221 MIR125A
35 miRNA mediated inhibition of translation GO:0035278 9.28 MIR17 MIR21 MIR210 MIR221 MIR222 MIR30A

Molecular functions related to Endocrine System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR9-1 MIR483 MIR31 MIR30A MIR222 MIR221

Sources for Endocrine System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....